Gyre Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.27 million for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2015-07-31
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-06-30 was -$2.18M.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-03-31 was $907.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-12-31 was $180.00K, a 50.41% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-09-30 was -$4.04M, a 299.65% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was -$7.21M, a 463.32% decline from fiscal 2013.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was $1.99M.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was -$11.52M, a 360.58% decline from fiscal 2011.
- Gyre Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2011 was $4.42M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2015-06-30 | -$2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$1.27M 10-Q · filed 2015-07-31 | -$1.09M derived: sum of 3 quarters · filed 2015-07-31 | -$5.13M derived: sum of 4 quarters · filed 2015-07-31 |
| 2015-03-31 | $907.00K 10-Q · filed 2015-05-07 | $1.09M derived: sum of 2 quarters · filed 2015-05-07 | -$2.95M derived: sum of 3 quarters · filed 2015-05-07 | -$5.21M derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$3.86M derived: sum of 2 quarters · filed 2015-03-16 | -$6.11M derived: sum of 3 quarters · filed 2015-07-31 | -$7.21M 10-K · filed 2015-03-16 |
| 2014-09-30 | -$4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$6.29M derived: sum of 2 quarters · filed 2015-07-31 | -$7.39M 10-Q · filed 2014-11-06 | -$7.03M derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$3.35M 10-Q · filed 2015-07-31 | -$2.99M derived: sum of 3 quarters · filed 2015-07-31 | -$967.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-03-31 | -$1.10M 10-Q · filed 2015-05-07 | -$735.00K derived: sum of 2 quarters · filed 2015-05-07 | $1.29M derived: sum of 3 quarters · filed 2015-05-07 | $1.51M derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $2.39M derived: sum of 2 quarters · filed 2015-03-16 | $2.61M derived: sum of 3 quarters · filed 2015-03-16 | $1.99M 10-K · filed 2015-03-16 |
| 2013-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $2.25M derived: sum of 2 quarters · filed 2014-11-06 | $1.62M 10-Q · filed 2014-11-06 | $3.15M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$401.00K 10-Q · filed 2014-08-07 | $1.13M derived: sum of 3 quarters · filed 2015-03-16 | -$1.19M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | -$627.00K 10-Q · filed 2014-05-08 | $905.00K derived: sum of 2 quarters · filed 2015-03-16 | -$1.42M derived: sum of 3 quarters · filed 2015-03-16 | -$3.87M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$791.00K derived: sum of 2 quarters · filed 2015-03-16 | -$3.24M derived: sum of 3 quarters · filed 2015-03-16 | -$11.52M 10-K · filed 2015-03-16 |
| 2012-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | -$4.77M derived: sum of 2 quarters · filed 2013-11-06 | -$13.05M 10-Q · filed 2013-11-06 | -$10.93M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | -$2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | -$10.72M 10-Q · filed 2013-08-07 | -$8.61M derived: sum of 3 quarters · filed 2014-03-14 | -$4.73M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | -$8.27M 10-Q · filed 2013-05-08 | -$6.16M derived: sum of 2 quarters · filed 2014-03-14 | -$2.28M derived: sum of 3 quarters · filed 2014-03-14 | -$4.32M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $5.99M derived: sum of 2 quarters · filed 2014-03-14 | $3.95M derived: sum of 3 quarters · filed 2014-03-14 | $4.42M 10-K · filed 2014-03-14 |
| 2011-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $1.83M derived: sum of 2 quarters · filed 2012-11-08 | $2.30M 10-Q · filed 2012-11-08 | $8.82M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$1.57M 10-Q · filed 2012-08-09 | $4.95M derived: sum of 3 quarters · filed 2013-03-15 | $6.60M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $466.00K 10-Q · filed 2012-05-09 | $6.99M derived: sum of 2 quarters · filed 2013-03-15 | $8.63M derived: sum of 3 quarters · filed 2013-03-15 | |
| 2010-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $8.17M derived: sum of 2 quarters · filed 2013-03-15 | -$3.80M 10-K · filed 2013-03-15 | |
| 2010-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$10.33M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | -$11.97M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $16.55M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |